Last updated: September 7, 2026
Rilonacept, marketed as Arcalyst, has shifted from a niche biologic for cryopyrin-associated periodic syndromes into a higher-value cardiovascular immunology product driven by recurrent pericarditis. Kiniksa Pharmaceuticals controls U.S. commercialization and has expanded sales rapidly through disease awareness, specialist targeting, and chronic-use demand. The principal commercial risks are concentration in one product, high annual treatment cost, payer controls, potential future biosimilar competition, and dependence on continued growth in recurrent pericarditis.
How large is the rilonacept market?
Rilonacept competes in a specialized IL-1 inhibition market rather than a broad inflammatory-disease segment. Its principal alternatives are anakinra, canakinumab, corticosteroids, colchicine, and immunosuppressive regimens used off label.
| Market attribute |
Rilonacept position |
| Brand |
Arcalyst |
| Active ingredient |
Rilonacept |
| Drug class |
Interleukin-1 inhibitor |
| Product type |
Recombinant fusion protein biologic |
| U.S. marketer |
Kiniksa Pharmaceuticals |
| Original developer |
Regeneron Pharmaceuticals |
| FDA pathway |
Biologics license application |
| Main approved markets |
CAPS, DIRA, recurrent pericarditis |
| Primary commercial growth driver |
Recurrent pericarditis |
| U.S. biosimilar status |
No approved biosimilar identified through the latest cited FDA materials |
| Orange Book status |
Not applicable as a BLA biologic; patent and exclusivity analysis belongs primarily in the Purple Book and FDA biologics framework |
Rilonacept is administered subcutaneously. Its weekly maintenance dosing is commercially important because it offers a more durable treatment schedule than daily injectable anakinra, although the two products are not interchangeable and have different clinical evidence profiles.
What FDA approvals support Arcalyst sales?
The FDA first approved Arcalyst in 2008 for cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome. The product later received approval for deficiency of interleukin-1 receptor antagonist, or DIRA, and recurrent pericarditis.
| FDA milestone |
Commercial effect |
| 2008 CAPS approval |
Established the original ultra-orphan franchise |
| 2016 DIRA approval |
Added a very rare pediatric and genetic indication |
| 2021 recurrent pericarditis approval |
Expanded the addressable population and created the main revenue growth engine |
| Post-approval recurrent-pericarditis uptake |
Moved Arcalyst from a niche rare-disease product toward a specialty cardiovascular immunology franchise |
The recurrent-pericarditis approval was based principally on the RHAPSODY program. The FDA label covers treatment of recurrent pericarditis and reduction in risk of recurrence in adults and adolescents aged 12 years and older weighing at least 40 kilograms.[1]
The indication changed the commercial profile of rilonacept. CAPS and DIRA are high-value but very small patient populations. Recurrent pericarditis creates a larger pool of patients who may require extended treatment and who can be identified through cardiology networks, specialty centers, and referral pathways.
How has Kiniksa’s rilonacept revenue changed?
Kiniksa’s financial trajectory has been dominated by Arcalyst. Revenue accelerated after the recurrent-pericarditis approval and subsequent commercial rollout.
| Period |
Financial trajectory |
Main driver |
| Before 2021 |
Limited specialty-product revenue |
CAPS and DIRA |
| 2021 |
Initial acceleration |
Recurrent-pericarditis launch |
| 2022 |
Strong growth |
Physician adoption and patient identification |
| 2023 |
Material scale-up |
Broader cardiology penetration and repeat treatment |
| 2024 |
Continued expansion |
Increased diagnosed-patient pool and commercial execution |
Kiniksa reported Arcalyst net product revenue of approximately $313 million in 2023, compared with approximately $200 million in 2022.[2] The company reported further growth in 2024, with Arcalyst sales approaching or exceeding the $400 million level based on company financial disclosures and investor materials.[3]
The exact reported figures can vary depending on whether the company presents net product revenue, total revenue, collaboration revenue, or rounded annual figures. The trend is consistent: Arcalyst became Kiniksa’s dominant asset and the primary source of operating leverage.
Why did revenue grow so quickly?
The main commercial factors were:
- Recurrent pericarditis created a substantially larger market than CAPS and DIRA.
- The product received disease-specific clinical validation through RHAPSODY.
- Weekly administration improved the product’s practical positioning against daily injectable IL-1 therapy.
- Recurrent pericarditis has a high recurrence burden and limited approved targeted therapies.
- Kiniksa built a specialized commercial infrastructure around cardiologists, rheumatologists, and high-volume referral centers.
- Patient support programs reduced reimbursement and onboarding friction.
The growth rate is unlikely to remain at launch-period levels indefinitely. Future performance depends on penetration into diagnosed patients, treatment duration, payer authorization, and the extent to which physicians use rilonacept earlier in the disease course.
What is the revenue outlook for rilonacept?
Rilonacept has a credible path to continued growth, but the revenue curve should become less steep as market penetration increases.
Bull-case growth drivers
The strongest upside factors are:
- Greater recognition of recurrent pericarditis as a distinct treatment population.
- Longer treatment duration among patients with recurrent disease.
- Expansion into additional age groups or related inflammatory cardiovascular conditions.
- Increased use in patients with multiple recurrences or steroid dependence.
- Stronger cardiology adoption outside major academic centers.
- Durable reimbursement for high-cost specialty therapy.
Base-case constraints
The commercial base case is constrained by:
- The small absolute number of eligible patients.
- High annual treatment cost.
- Prior authorization and step-therapy requirements.
- Competition from low-cost corticosteroids and colchicine.
- Off-label use of anakinra.
- Treatment discontinuation after disease control.
- Limited geographic commercialization compared with multinational biologic franchises.
Rilonacept is more likely to remain a high-value specialty product than become a mass-market biologic. Its revenue potential is significant because annual treatment value is high, but the addressable population remains narrower than markets for tumor necrosis factor inhibitors, interleukin-17 inhibitors, or interleukin-6 inhibitors.
What is the annual cost of rilonacept treatment?
The list price for Arcalyst is high and varies over time. Public pricing has generally placed annual therapy in the high five figures to low six figures before rebates, depending on loading dose, maintenance dosing, and price updates.[4]
The economic calculation differs by indication:
- CAPS and DIRA involve very small populations and can support orphan-drug pricing.
- Recurrent pericarditis has a larger population, but payers are more likely to impose authorization controls.
- The cost comparison is not limited to drug price. Hospitalizations, emergency visits, corticosteroid exposure, and repeat pericarditis episodes affect payer economics.
- A treatment that reduces recurrence may be economically attractive even when its acquisition cost is high, particularly in patients with frequent hospital or emergency utilization.
The key commercial question is whether payers view rilonacept as a recurrence-prevention therapy or as an expensive alternative to generic anti-inflammatory treatment. Kiniksa’s reimbursement strategy must support the first interpretation.
What patents protect rilonacept and Arcalyst?
Rilonacept patent protection is more complex than a single composition-of-matter patent. The relevant estate may include patents covering the protein, formulations, dosing regimens, treatment methods, and manufacturing processes.
The most commercially important protection now comes from:
- Method-of-use patents for recurrent pericarditis.
- Dosing and treatment-duration claims.
- Formulation and stability claims.
- Manufacturing and purification processes.
- Any surviving regulatory exclusivity or pediatric extensions.
- Trade secrets associated with biologic production and analytical methods.
Biologic patents can remain commercially relevant after the earliest composition patent expires because follow-on patents may create additional barriers to biosimilar launch. Their strength depends heavily on claim scope, written-description support, enablement, prosecution history, and whether the claims cover commercially used dosing regimens.
How strong is the rilonacept patent estate?
The estate is commercially meaningful but should not be treated as impenetrable. Rilonacept is a mature biologic, and the original product patents are older than the recurrent-pericarditis approval. Later method-of-use patents may be more important than the original molecular protection.
Patent strength is highest where claims:
- Cover the approved indication directly.
- Recite specific patient populations or recurrence-reduction outcomes.
- Match the marketed dose and treatment schedule.
- Avoid broad functional language vulnerable to enablement challenges.
- Are supported by the RHAPSODY clinical data.
Patent strength is weaker where claims:
- Cover broad IL-1 inhibition concepts.
- Depend on narrow treatment-duration limitations.
- Overlap with earlier clinical or scientific disclosures.
- Do not map cleanly onto the approved label.
- Can be designed around through a different dosing schedule or indication.
When does rilonacept lose exclusivity?
Rilonacept does not have one single loss-of-exclusivity date. The practical timing depends on several layers:
- Biologics regulatory exclusivity.
- Composition-of-matter patent expiry.
- Method-of-use patent expiry.
- Formulation and manufacturing patent expiry.
- Pediatric exclusivity, where applicable.
- Patent litigation and settlement terms.
- Biosimilar interchangeability and substitution rules.
For biologics approved under a BLA, the FDA grants 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, subject to statutory rules.[5] Rilonacept’s original approval dates make that exclusivity period largely historical rather than a near-term commercial barrier.
The more important forward-looking issue is whether later patents covering recurrent pericarditis treatment remain enforceable when a biosimilar applicant seeks approval. Patent expiry should be reviewed patent by patent rather than by relying on a single headline date.
Does Arcalyst have Orange Book-listed patents?
No conventional Orange Book analysis applies because Arcalyst is a biologic approved under a BLA rather than a small-molecule drug approved under an NDA.
The Orange Book primarily identifies approved drug products and patent information for NDA products. Biologic reference products and biosimilar exclusivity are evaluated through the FDA’s Purple Book and the BPCIA framework.[6]
For rilonacept, an investment-grade exclusivity review should examine:
- The Purple Book reference-product record.
- FDA approval history and exclusivity data.
- USPTO patent records.
- Kiniksa and Regeneron patent disclosures.
- Patent assignment and maintenance records.
- Any relevant federal-court litigation.
- Biosimilar application activity and patent notices.
Are there Paragraph IV challenges to rilonacept?
Paragraph IV certification is an abbreviated new drug application mechanism for small-molecule products. It is not the standard pathway for a biosimilar to a BLA product.
A rilonacept biosimilar applicant would generally proceed under the BPCIA, not through a traditional ANDA Paragraph IV challenge. The relevant process involves a biosimilar application, patent-exchange procedures, and potential patent litigation under the BPCIA framework.
No approved rilonacept biosimilar or publicly established biosimilar launch date is identified in the cited FDA materials. The absence of an approved biosimilar does not eliminate future risk. Rilonacept’s commercial value and high treatment price can justify development by companies with biologic manufacturing capabilities.
What biosimilar risks affect rilonacept?
The first credible biosimilar threat is more likely to affect price and contracting than cause an immediate collapse in volume.
Biosimilar entry risks
A future competitor would need to address:
- Complex fusion-protein characterization.
- Functional IL-1 binding and neutralization.
- Glycosylation and higher-order structure.
- Subcutaneous delivery and injection-device performance.
- Immunogenicity.
- Comparability of pharmacokinetic and pharmacodynamic attributes.
- Interchangeability requirements, if substitution is sought.
Manufacturing is a meaningful barrier. Rilonacept is not a simple monoclonal antibody with a large established biosimilar ecosystem. Development requires validated cell-line, fermentation, purification, formulation, and analytical processes.
Likely commercial sequence
A likely sequence is:
- A biosimilar developer targets the recurrent-pericarditis opportunity.
- The reference sponsor uses patent litigation and contracting to delay or narrow launch.
- The entrant initially discounts modestly because the patient population is specialized.
- Payers use the biosimilar to negotiate rebates.
- Net price erosion develops before substantial unit displacement.
Kiniksa’s exposure would depend on how much of Arcalyst revenue is protected by indication-specific patents and how strongly prescribers value the reference product’s clinical history.
Does rilonacept face generic competition?
Traditional generic competition is not the principal threat. Rilonacept is a biologic, so the relevant competitor is a biosimilar or interchangeable biosimilar.
Off-label competition is more immediate:
| Competitor |
Competitive role |
| Anakinra |
Daily injectable IL-1 antagonist; lower-cost, off-label alternative |
| Canakinumab |
Long-acting IL-1β inhibitor; high-cost alternative with different approved uses |
| Colchicine |
Low-cost standard therapy for many pericarditis patients |
| Corticosteroids |
Low-cost option but associated with relapse and systemic adverse effects |
| Immunosuppressants |
Used in refractory or selected inflammatory cases |
Anakinra is the most important pharmacologic substitute in the IL-1 category. Rilonacept’s commercial differentiation is based on weekly dosing, approved recurrent-pericarditis efficacy, and recurrence-reduction data rather than on broad superiority across all inflammatory diseases.
What licensing deals affect rilonacept economics?
Kiniksa obtained rights to commercialize Arcalyst through an agreement with Regeneron. The agreement transferred or granted commercial rights while preserving economic participation for Regeneron through royalty arrangements.[7]
This structure has two effects:
- Kiniksa can commercialize the product without having developed the original biologic from inception.
- Kiniksa’s gross-to-net economics are reduced by royalties and other contractual obligations.
The agreement also creates strategic dependence on Regeneron for certain intellectual-property and product-related matters. For valuation purposes, Arcalyst revenue should not be treated as fully retained product revenue without reviewing royalty rates, milestone obligations, territory limitations, and termination provisions.
What litigation and settlement risks affect Arcalyst?
The principal future litigation risk is likely to arise from biosimilar patent disputes rather than conventional Paragraph IV litigation. Potential claims could cover:
- Approved recurrent-pericarditis treatment methods.
- Dose and administration schedules.
- Formulation characteristics.
- Manufacturing methods.
- Patent-enforceability and obviousness defenses.
- Written description and enablement.
- Patent-term calculations.
A settlement could permit an agreed biosimilar launch date before the latest asserted patent expiry. The commercial effect would depend on whether the settlement allows a single authorized entrant or multiple competitors.
No major publicly established biosimilar settlement date is identified in the cited materials. That status can change quickly if a biosimilar application is filed and the BPCIA patent process begins.
What is the competitive landscape for Kiniksa?
Kiniksa has built a concentrated but commercially coherent portfolio. Arcalyst is the main revenue asset, while other pipeline or commercial programs provide diversification but do not currently reduce the company’s dependence on rilonacept to the same extent as a multi-product pharmaceutical company.
The company’s competitive position is strongest in:
- Recurrent pericarditis specialists.
- Patients with repeated recurrence.
- Steroid-dependent patients.
- Patients who require targeted IL-1 inhibition.
- Centers with established reimbursement and diagnosis pathways.
Its position is weaker in:
- First-episode pericarditis.
- Patients controlled with inexpensive colchicine.
- Markets with limited specialty-drug reimbursement.
- Patients unable to sustain long-term injections.
- Regions where Kiniksa lacks direct commercial infrastructure.
How much revenue is exposed to rilonacept?
Rilonacept represents the overwhelming majority of Kiniksa’s commercial revenue. This concentration creates operating leverage but also amplifies product-specific risk.
| Exposure category |
Assessment |
| Revenue concentration |
High |
| Dependence on one approved product |
High |
| Dependence on recurrent pericarditis |
High |
| Manufacturing concentration |
Meaningful |
| Payer exposure |
High |
| Near-term biosimilar risk |
Limited but rising over time |
| Long-term patent risk |
Material |
| Regulatory risk |
Moderate |
| Clinical differentiation |
Strongest in recurrent pericarditis |
Revenue growth can translate into significant margin expansion because commercial infrastructure does not need to grow proportionally with sales. The opposite is also true: a reimbursement change, safety signal, manufacturing interruption, or competing biologic can affect the company disproportionately.
What are the most likely rilonacept launch scenarios?
Scenario 1: Continued branded expansion
Kiniksa continues to grow through broader diagnosis, longer treatment duration, and deeper cardiology penetration. This scenario supports sustained revenue growth and margin expansion.
Scenario 2: Slower growth with payer pressure
The product remains clinically preferred for recurrent disease, but payers require more documentation and step therapy. Revenue grows at a lower rate, with higher rebate pressure.
Scenario 3: Authorized biosimilar entry
A biosimilar launches after patent settlement or litigation. Net pricing declines first, followed by gradual volume share loss. The effect is manageable if Kiniksa retains strong specialist preference.
Scenario 4: Multiple biosimilar entrants
Several biosimilars enter after key patent barriers expire. This creates sharper price erosion and may materially reduce Arcalyst revenue, particularly in payer-controlled channels.
Key Takeaways
- Arcalyst transformed rilonacept from an ultra-orphan product into a specialty cardiovascular biologic.
- Recurrent pericarditis is the central driver of Kiniksa’s revenue growth.
- Kiniksa’s Arcalyst revenue increased from roughly $200 million in 2022 to approximately $313 million in 2023, with further growth reported in 2024.[2][3]
- The product has high annual treatment value but a limited, specialist-driven patient population.
- Orange Book and Paragraph IV analysis do not directly apply because rilonacept is a BLA biologic.
- Future competition will come from biosimilars, anakinra, colchicine, corticosteroids, and other anti-inflammatory regimens.
- Patent value is concentrated in recurrent-pericarditis method-of-use, formulation, dosing, and manufacturing claims.
- Kiniksa’s financial exposure to one biologic remains high.
- The most important valuation variables are recurrent-pericarditis penetration, treatment duration, payer access, royalty economics, and biosimilar timing.
FAQs
Is rilonacept a biologic or a small-molecule drug?
Rilonacept is a recombinant fusion-protein biologic approved by the FDA under a BLA. It is not a conventional small-molecule drug eligible for ordinary generic substitution.
What drug is most similar to rilonacept?
Anakinra is the closest pharmacologic alternative because both products inhibit the interleukin-1 pathway. Anakinra is administered daily and is used off label in recurrent pericarditis, while rilonacept has an FDA-approved recurrent-pericarditis indication and weekly maintenance dosing.
Can a biosimilar be substituted automatically for Arcalyst?
Automatic substitution depends on FDA interchangeability status and state pharmacy-substitution law. A biosimilar may be approved without being designated interchangeable.
Is rilonacept approved for acute pericarditis?
Arcalyst is approved for recurrent pericarditis, not for every patient with an initial acute pericarditis episode. Prescribing decisions depend on the FDA label, clinical evidence, and patient-specific factors.
Who owns the commercial rights to Arcalyst?
Kiniksa commercializes Arcalyst in the United States under its relationship with Regeneron. The arrangement includes economic and contractual obligations that affect Kiniksa’s retained product economics.
References
- U.S. Food and Drug Administration. (2021). Arcalyst (rilonacept) prescribing information.
- Kiniksa Pharmaceuticals, Ltd. (2024). Annual report on Form 10-K for the year ended December 31, 2023. U.S. Securities and Exchange Commission.
- Kiniksa Pharmaceuticals, Ltd. (2025). Annual report on Form 10-K for the year ended December 31, 2024. U.S. Securities and Exchange Commission.
- Kiniksa Pharmaceuticals, Ltd. (2024). Arcalyst product and reimbursement information.
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Regeneron Pharmaceuticals, Inc., & Kiniksa Pharmaceuticals, Ltd. (2017). Collaboration and license agreement relating to Arcalyst.
